Abstract
In baboons, the intravenous administration of piribedil, a dopaminergic agonist, was associated with marked dose dependent increases in CBF and cerebral oxygen consumption. We have studied the effects of piribedil on CBF in 20 normal, human volunteers of comparable ages. Ten received 0.1 mg/kg piribedil intravenously for 30 min; the other ten received 0.2 mg/kg. In the first group, CBF did not vary significantly, in the second group, there was a mean increase in CBF of 21.8% (p less than or equal to 0.005). In man, as in animals, piribedil provokes an increase of CBF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
